Tin tức & Cập nhật

New drug applications approved by US FDA as of 1-15 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A multi-omics study by researchers from Japan has found that blood type B (BTB) is associated with reduced immune checkpoint inhibitor (ICI) efficacy in first-line (1L) treatment of head and neck squamous cell carcinoma (HNSCC).

A study using data from the MESA* cohort shows an association between subclinical cardiac remodeling and increased risk of cancer.

Longer-term follow-up of the phase II ARTEMIS-002 trial continues to show promising efficacy of risvutatug rezetecan (ris-rez) in relapsed or refractory (R/R) sarcoma, with median overall survival (OS) reaching about 2 years, according to data presented at ESMO TAT Asia 2026.

Use of bidi either exclusively or along with other tobacco products carries increased cancer risk, as reported in an observational study in India.

Upadacitinib demonstrates its noninferiority to tofacitinib in improving lung transplantation-free survival (LTFS) at 6 months among patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease (MDA5+DM-ILD), reports a study.